Short Interest in Agile Therapeutics, Inc. (NASDAQ:AGRX) Rises By 62.7%

Agile Therapeutics, Inc. (NASDAQ:AGRX) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 361,300 shares, an increase of 62.7% from the February 29th total of 222,100 shares. Based on an average daily volume of 698,200 shares, the days-to-cover ratio is presently 0.5 days. Currently, 12.7% of the company’s stock are short sold.

Agile Therapeutics Stock Down 8.1 %

AGRX opened at $0.34 on Friday. The firm has a market cap of $1.01 million, a price-to-earnings ratio of -0.03 and a beta of 1.51. The business’s 50 day moving average is $0.98 and its two-hundred day moving average is $1.62. Agile Therapeutics has a 52 week low of $0.20 and a 52 week high of $12.15.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AGRX. StockNews.com cut Agile Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th. Maxim Group restated a “hold” rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Armistice Capital LLC increased its holdings in shares of Agile Therapeutics by 10.2% in the fourth quarter. Armistice Capital LLC now owns 108,000 shares of the specialty pharmaceutical company’s stock valued at $211,000 after purchasing an additional 10,000 shares during the period. State Street Corp acquired a new position in shares of Agile Therapeutics in the second quarter valued at approximately $32,000. BlackRock Inc. increased its holdings in shares of Agile Therapeutics by 1.1% in the first quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock valued at $319,000 after purchasing an additional 16,104 shares during the period. Vanguard Group Inc. acquired a new position in shares of Agile Therapeutics in the fourth quarter valued at approximately $40,000. Finally, Jane Street Group LLC acquired a new position in shares of Agile Therapeutics in the second quarter valued at approximately $108,000. Institutional investors and hedge funds own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.